| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Space Flight | 72 | 2026 | 172 | 36.110 |
Why?
|
| Ophthalmology | 74 | 2025 | 177 | 22.180 |
Why?
|
| Papilledema | 48 | 2026 | 84 | 18.390 |
Why?
|
| Weightlessness | 42 | 2026 | 86 | 18.100 |
Why?
|
| Eye Diseases | 38 | 2025 | 108 | 15.330 |
Why?
|
| Vision Disorders | 60 | 2026 | 197 | 14.900 |
Why?
|
| Optic Nerve Diseases | 31 | 2025 | 80 | 13.980 |
Why?
|
| Pseudotumor Cerebri | 33 | 2024 | 64 | 13.790 |
Why?
|
| Giant Cell Arteritis | 30 | 2025 | 48 | 13.680 |
Why?
|
| Visual Acuity | 61 | 2026 | 537 | 12.110 |
Why?
|
| Astronauts | 39 | 2025 | 79 | 11.850 |
Why?
|
| Visual Fields | 33 | 2025 | 141 | 8.250 |
Why?
|
| Optic Neuritis | 13 | 2024 | 34 | 7.860 |
Why?
|
| Optic Neuropathy, Ischemic | 21 | 2026 | 46 | 7.440 |
Why?
|
| Humans | 527 | 2026 | 131671 | 7.210 |
Why?
|
| Artificial Intelligence | 21 | 2025 | 329 | 7.000 |
Why?
|
| Ophthalmoplegia | 18 | 2024 | 52 | 6.940 |
Why?
|
| Intracranial Hypertension | 20 | 2025 | 135 | 6.600 |
Why?
|
| Optic Disk | 15 | 2026 | 46 | 6.410 |
Why?
|
| Optic Nerve | 26 | 2024 | 115 | 6.360 |
Why?
|
| Magnetic Resonance Imaging | 109 | 2025 | 3917 | 6.260 |
Why?
|
| Hemianopsia | 16 | 2023 | 25 | 6.150 |
Why?
|
| Blindness | 19 | 2025 | 72 | 5.590 |
Why?
|
| Tomography, Optical Coherence | 35 | 2026 | 463 | 5.340 |
Why?
|
| Intracranial Pressure | 24 | 2026 | 215 | 5.160 |
Why?
|
| Meningioma | 10 | 2023 | 135 | 4.990 |
Why?
|
| Strabismus | 10 | 2025 | 64 | 4.960 |
Why?
|
| Abducens Nerve Diseases | 7 | 2025 | 12 | 4.690 |
Why?
|
| Clinical Competence | 38 | 2025 | 1052 | 4.650 |
Why?
|
| Eye | 19 | 2025 | 227 | 4.590 |
Why?
|
| Neurology | 12 | 2024 | 121 | 4.570 |
Why?
|
| Orbital Diseases | 11 | 2025 | 66 | 4.400 |
Why?
|
| Eye Injuries | 5 | 2026 | 49 | 4.260 |
Why?
|
| Meningeal Neoplasms | 8 | 2023 | 206 | 4.070 |
Why?
|
| Internship and Residency | 35 | 2025 | 1215 | 4.070 |
Why?
|
| Retinal Diseases | 11 | 2024 | 151 | 3.940 |
Why?
|
| Education, Medical, Graduate | 28 | 2025 | 546 | 3.900 |
Why?
|
| Embolization, Therapeutic | 10 | 2022 | 224 | 3.710 |
Why?
|
| Optic Atrophy | 8 | 2023 | 46 | 3.650 |
Why?
|
| Nystagmus, Pathologic | 8 | 2023 | 23 | 3.620 |
Why?
|
| Pituitary Neoplasms | 7 | 2024 | 78 | 3.550 |
Why?
|
| Syndrome | 25 | 2026 | 1168 | 3.540 |
Why?
|
| Ocular Motility Disorders | 8 | 2023 | 37 | 3.510 |
Why?
|
| Exotropia | 6 | 2023 | 21 | 3.390 |
Why?
|
| Skull Base Neoplasms | 6 | 2025 | 37 | 3.350 |
Why?
|
| Educational Measurement | 25 | 2025 | 317 | 3.300 |
Why?
|
| Temporal Arteries | 17 | 2024 | 31 | 3.240 |
Why?
|
| Dry Eye Syndromes | 7 | 2025 | 293 | 3.020 |
Why?
|
| Macular Degeneration | 5 | 2024 | 91 | 2.960 |
Why?
|
| Horner Syndrome | 6 | 2024 | 14 | 2.940 |
Why?
|
| Retinal Artery Occlusion | 8 | 2023 | 15 | 2.830 |
Why?
|
| Eye Movements | 6 | 2025 | 69 | 2.810 |
Why?
|
| Carotid-Cavernous Sinus Fistula | 5 | 2022 | 11 | 2.800 |
Why?
|
| Cranial Nerve Diseases | 4 | 2025 | 28 | 2.740 |
Why?
|
| Biopsy | 28 | 2024 | 1252 | 2.710 |
Why?
|
| Oculomotor Muscles | 9 | 2025 | 81 | 2.620 |
Why?
|
| Orbit | 8 | 2023 | 81 | 2.590 |
Why?
|
| Diplopia | 13 | 2024 | 43 | 2.580 |
Why?
|
| Football | 3 | 2024 | 36 | 2.470 |
Why?
|
| Trochlear Nerve Diseases | 4 | 2025 | 5 | 2.430 |
Why?
|
| Hydrocephalus | 4 | 2023 | 292 | 2.410 |
Why?
|
| Optic Atrophy, Hereditary, Leber | 5 | 2022 | 13 | 2.370 |
Why?
|
| Anemia | 5 | 2023 | 355 | 2.370 |
Why?
|
| Optic Nerve Neoplasms | 5 | 2023 | 15 | 2.350 |
Why?
|
| Curriculum | 17 | 2024 | 783 | 2.280 |
Why?
|
| Ophthalmologists | 4 | 2024 | 11 | 2.280 |
Why?
|
| Pupil Disorders | 5 | 2023 | 18 | 2.280 |
Why?
|
| Education, Medical | 8 | 2024 | 288 | 2.260 |
Why?
|
| Neuromyelitis Optica | 3 | 2025 | 33 | 2.250 |
Why?
|
| Aerospace Medicine | 6 | 2024 | 39 | 2.220 |
Why?
|
| Visual Field Tests | 17 | 2023 | 50 | 2.170 |
Why?
|
| Middle Aged | 86 | 2026 | 28886 | 2.150 |
Why?
|
| Ophthalmologic Surgical Procedures | 12 | 2023 | 94 | 2.150 |
Why?
|
| Female | 120 | 2026 | 71181 | 2.130 |
Why?
|
| Myasthenia Gravis | 4 | 2023 | 69 | 2.120 |
Why?
|
| Male | 118 | 2026 | 65264 | 2.090 |
Why?
|
| Adult | 77 | 2026 | 31717 | 2.090 |
Why?
|
| Glaucoma | 6 | 2023 | 86 | 2.080 |
Why?
|
| Corneal Injuries | 4 | 2024 | 35 | 2.060 |
Why?
|
| Face | 7 | 2023 | 196 | 2.060 |
Why?
|
| Diagnosis, Differential | 36 | 2023 | 1911 | 2.020 |
Why?
|
| Competency-Based Education | 12 | 2015 | 75 | 1.970 |
Why?
|
| Teaching | 10 | 2019 | 195 | 1.970 |
Why?
|
| Oculomotor Nerve Diseases | 6 | 2024 | 16 | 1.960 |
Why?
|
| Brain | 19 | 2025 | 3239 | 1.930 |
Why?
|
| Retinal Vein Occlusion | 6 | 2023 | 8 | 1.920 |
Why?
|
| Carbonic Anhydrase Inhibitors | 5 | 2024 | 27 | 1.810 |
Why?
|
| Miller Fisher Syndrome | 3 | 2021 | 3 | 1.790 |
Why?
|
| Multiple Sclerosis | 3 | 2024 | 390 | 1.780 |
Why?
|
| Macula Lutea | 4 | 2024 | 25 | 1.770 |
Why?
|
| Fluorescein Angiography | 13 | 2026 | 65 | 1.760 |
Why?
|
| Lymphoma, B-Cell | 3 | 2021 | 149 | 1.740 |
Why?
|
| Aged | 56 | 2026 | 21256 | 1.740 |
Why?
|
| Students, Medical | 4 | 2021 | 350 | 1.730 |
Why?
|
| Scotoma | 5 | 2022 | 16 | 1.690 |
Why?
|
| Typhus, Endemic Flea-Borne | 3 | 2021 | 28 | 1.690 |
Why?
|
| Meningitis, Cryptococcal | 3 | 2021 | 19 | 1.640 |
Why?
|
| Delivery of Health Care | 10 | 2024 | 684 | 1.630 |
Why?
|
| Tears | 4 | 2025 | 185 | 1.610 |
Why?
|
| Optic Chiasm | 4 | 2024 | 13 | 1.610 |
Why?
|
| Lower Body Negative Pressure | 2 | 2024 | 5 | 1.600 |
Why?
|
| Infarction, Posterior Cerebral Artery | 2 | 2023 | 2 | 1.590 |
Why?
|
| Chordoma | 2 | 2025 | 18 | 1.580 |
Why?
|
| Cranial Fossa, Posterior | 3 | 2025 | 25 | 1.570 |
Why?
|
| Thymoma | 2 | 2023 | 21 | 1.560 |
Why?
|
| Esotropia | 4 | 2023 | 19 | 1.550 |
Why?
|
| Lens, Crystalline | 2 | 2023 | 101 | 1.550 |
Why?
|
| Head | 3 | 2023 | 115 | 1.540 |
Why?
|
| Thymus Neoplasms | 2 | 2023 | 39 | 1.540 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 3 | 2021 | 21 | 1.530 |
Why?
|
| Vasculitis | 2 | 2024 | 47 | 1.510 |
Why?
|
| Pituitary Apoplexy | 2 | 2022 | 2 | 1.500 |
Why?
|
| Athletic Injuries | 2 | 2026 | 69 | 1.500 |
Why?
|
| Thalamus | 4 | 2022 | 87 | 1.500 |
Why?
|
| Tomography, X-Ray Computed | 25 | 2025 | 2120 | 1.490 |
Why?
|
| Cataract | 2 | 2023 | 152 | 1.480 |
Why?
|
| Adenoma | 4 | 2022 | 145 | 1.470 |
Why?
|
| Takayasu Arteritis | 3 | 2024 | 11 | 1.470 |
Why?
|
| Acetazolamide | 8 | 2024 | 27 | 1.460 |
Why?
|
| Education, Medical, Undergraduate | 3 | 2020 | 173 | 1.460 |
Why?
|
| Eyelid Diseases | 3 | 2022 | 58 | 1.460 |
Why?
|
| Wernicke Encephalopathy | 3 | 2022 | 4 | 1.460 |
Why?
|
| Neuroimaging | 7 | 2025 | 404 | 1.440 |
Why?
|
| Headache | 7 | 2021 | 110 | 1.430 |
Why?
|
| Machine Learning | 4 | 2024 | 375 | 1.420 |
Why?
|
| Vertebrobasilar Insufficiency | 2 | 2023 | 8 | 1.410 |
Why?
|
| Aged, 80 and over | 26 | 2025 | 6922 | 1.400 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 5 | 2024 | 36 | 1.390 |
Why?
|
| Ophthalmic Artery | 3 | 2021 | 17 | 1.350 |
Why?
|
| Brain Neoplasms | 8 | 2022 | 1298 | 1.340 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 5 | 2025 | 84 | 1.340 |
Why?
|
| Carotid Artery Diseases | 2 | 2022 | 132 | 1.320 |
Why?
|
| Autoantibodies | 9 | 2024 | 466 | 1.310 |
Why?
|
| Geriatrics | 3 | 2020 | 71 | 1.300 |
Why?
|
| Ependymoma | 2 | 2022 | 153 | 1.290 |
Why?
|
| Accreditation | 9 | 2014 | 89 | 1.290 |
Why?
|
| United States | 41 | 2026 | 11802 | 1.280 |
Why?
|
| Eye Infections, Bacterial | 6 | 2025 | 79 | 1.270 |
Why?
|
| Autoimmune Diseases | 3 | 2021 | 275 | 1.260 |
Why?
|
| Hallucinations | 2 | 2024 | 25 | 1.260 |
Why?
|
| Pandemics | 9 | 2023 | 1164 | 1.250 |
Why?
|
| Neuroma, Acoustic | 2 | 2022 | 29 | 1.240 |
Why?
|
| Retrospective Studies | 45 | 2025 | 17667 | 1.240 |
Why?
|
| Cerebral Infarction | 4 | 2020 | 46 | 1.230 |
Why?
|
| Vision, Binocular | 4 | 2023 | 31 | 1.220 |
Why?
|
| Glaucoma, Angle-Closure | 3 | 2025 | 13 | 1.220 |
Why?
|
| Fundus Oculi | 6 | 2021 | 35 | 1.220 |
Why?
|
| Weightlessness Simulation | 2 | 2026 | 23 | 1.170 |
Why?
|
| Hearing Loss, Sensorineural | 2 | 2022 | 155 | 1.170 |
Why?
|
| Compartment Syndromes | 3 | 2025 | 33 | 1.150 |
Why?
|
| Reflex, Pupillary | 2 | 2022 | 17 | 1.150 |
Why?
|
| Fellowships and Scholarships | 4 | 2022 | 324 | 1.150 |
Why?
|
| Multiple Myeloma | 3 | 2024 | 217 | 1.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 577 | 1.140 |
Why?
|
| Blindness, Cortical | 4 | 2021 | 15 | 1.140 |
Why?
|
| Nervous System Diseases | 3 | 2024 | 403 | 1.130 |
Why?
|
| Choroid Diseases | 4 | 2017 | 17 | 1.130 |
Why?
|
| Waldenstrom Macroglobulinemia | 2 | 2021 | 152 | 1.120 |
Why?
|
| Reflex, Vestibulo-Ocular | 2 | 2025 | 16 | 1.120 |
Why?
|
| Glucocorticoids | 12 | 2024 | 350 | 1.120 |
Why?
|
| Cerebrospinal Fluid Pressure | 3 | 2025 | 18 | 1.100 |
Why?
|
| Spinal Puncture | 6 | 2021 | 51 | 1.100 |
Why?
|
| Postoperative Complications | 9 | 2023 | 3130 | 1.090 |
Why?
|
| Retinitis | 2 | 2021 | 12 | 1.090 |
Why?
|
| Refractive Errors | 2 | 2025 | 59 | 1.080 |
Why?
|
| Blepharospasm | 2 | 2019 | 47 | 1.080 |
Why?
|
| Cavernous Sinus | 4 | 2021 | 24 | 1.070 |
Why?
|
| Hyperopia | 3 | 2017 | 59 | 1.070 |
Why?
|
| Retina | 4 | 2024 | 462 | 1.070 |
Why?
|
| Diabetic Retinopathy | 4 | 2026 | 84 | 1.060 |
Why?
|
| Visual Pathways | 2 | 2025 | 80 | 1.060 |
Why?
|
| Disease Management | 2 | 2025 | 564 | 1.060 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 180 | 1.050 |
Why?
|
| Refraction, Ocular | 3 | 2025 | 184 | 1.050 |
Why?
|
| Pregnancy Complications | 3 | 2023 | 547 | 1.040 |
Why?
|
| Intraocular Pressure | 9 | 2025 | 133 | 1.040 |
Why?
|
| Vision, Ocular | 4 | 2025 | 127 | 1.040 |
Why?
|
| Basilar Artery | 2 | 2023 | 18 | 1.030 |
Why?
|
| Follow-Up Studies | 17 | 2025 | 5297 | 1.020 |
Why?
|
| Malus | 5 | 2024 | 12 | 1.020 |
Why?
|
| Ultrasonography | 6 | 2024 | 974 | 1.010 |
Why?
|
| Acute Disease | 10 | 2025 | 1153 | 1.000 |
Why?
|
| Retinal Ganglion Cells | 6 | 2025 | 117 | 0.990 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 2 | 2025 | 4 | 0.980 |
Why?
|
| Stroke | 3 | 2025 | 1049 | 0.980 |
Why?
|
| Migraine Disorders | 2 | 2018 | 64 | 0.970 |
Why?
|
| Immobilization | 1 | 2026 | 23 | 0.960 |
Why?
|
| Telemedicine | 3 | 2024 | 523 | 0.950 |
Why?
|
| Tuberculosis, Meningeal | 2 | 2023 | 31 | 0.950 |
Why?
|
| Radiation Injuries | 2 | 2023 | 146 | 0.940 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2018 | 207 | 0.930 |
Why?
|
| Central Nervous System | 2 | 2025 | 286 | 0.930 |
Why?
|
| Brain Concussion | 2 | 2020 | 240 | 0.930 |
Why?
|
| Lymphoma | 2 | 2019 | 330 | 0.930 |
Why?
|
| Intracranial Aneurysm | 3 | 2021 | 82 | 0.920 |
Why?
|
| Social Media | 2 | 2025 | 119 | 0.920 |
Why?
|
| Neuromuscular Junction | 1 | 2026 | 96 | 0.920 |
Why?
|
| Nanomedicine | 1 | 2025 | 27 | 0.920 |
Why?
|
| Eye Pain | 5 | 2024 | 11 | 0.920 |
Why?
|
| Polyarteritis Nodosa | 2 | 2024 | 10 | 0.910 |
Why?
|
| Tensile Strength | 1 | 2025 | 46 | 0.910 |
Why?
|
| Delayed Diagnosis | 3 | 2023 | 129 | 0.910 |
Why?
|
| Biomarkers | 7 | 2025 | 3405 | 0.910 |
Why?
|
| Cornea | 3 | 2024 | 566 | 0.900 |
Why?
|
| Polydipsia | 1 | 2025 | 5 | 0.900 |
Why?
|
| Anterior Eye Segment | 1 | 2025 | 24 | 0.900 |
Why?
|
| Alexia, Pure | 2 | 2022 | 3 | 0.900 |
Why?
|
| Muscular Atrophy | 1 | 2026 | 83 | 0.890 |
Why?
|
| Meningitis, Aseptic | 2 | 2021 | 13 | 0.890 |
Why?
|
| Optic Atrophy, Autosomal Dominant | 2 | 2021 | 11 | 0.890 |
Why?
|
| Spacecraft | 1 | 2024 | 2 | 0.880 |
Why?
|
| Athletic Performance | 1 | 2024 | 13 | 0.880 |
Why?
|
| Retinal Vessels | 4 | 2022 | 52 | 0.880 |
Why?
|
| Eye Infections, Fungal | 2 | 2016 | 68 | 0.880 |
Why?
|
| Hypercapnia | 1 | 2024 | 23 | 0.870 |
Why?
|
| Polycythemia | 1 | 2025 | 45 | 0.870 |
Why?
|
| Graves Ophthalmopathy | 2 | 2019 | 17 | 0.870 |
Why?
|
| Triage | 1 | 2026 | 153 | 0.870 |
Why?
|
| Moon | 1 | 2024 | 13 | 0.860 |
Why?
|
| Kidney Calculi | 1 | 2024 | 46 | 0.860 |
Why?
|
| Sunlight | 1 | 2024 | 27 | 0.860 |
Why?
|
| Diet, Vegan | 1 | 2024 | 2 | 0.850 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2024 | 903 | 0.850 |
Why?
|
| Charles Bonnet Syndrome | 1 | 2024 | 1 | 0.850 |
Why?
|
| El Nino-Southern Oscillation | 1 | 2024 | 1 | 0.840 |
Why?
|
| United States National Aeronautics and Space Administration | 1 | 2024 | 17 | 0.840 |
Why?
|
| Eye Injuries, Penetrating | 1 | 2024 | 16 | 0.840 |
Why?
|
| Antioxidants | 2 | 2023 | 336 | 0.840 |
Why?
|
| Eye Burns | 1 | 2024 | 16 | 0.840 |
Why?
|
| Cerebral Ventricle Neoplasms | 2 | 2022 | 14 | 0.840 |
Why?
|
| Drug Delivery Systems | 1 | 2025 | 211 | 0.840 |
Why?
|
| Brain-Computer Interfaces | 1 | 2024 | 15 | 0.840 |
Why?
|
| Occipital Lobe | 3 | 2020 | 35 | 0.830 |
Why?
|
| Ophthalmic Solutions | 1 | 2024 | 88 | 0.830 |
Why?
|
| Visual Perception | 1 | 2024 | 128 | 0.820 |
Why?
|
| Hypertension | 3 | 2023 | 1360 | 0.820 |
Why?
|
| Anemia, Pernicious | 1 | 2023 | 1 | 0.820 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2023 | 20 | 0.820 |
Why?
|
| Paraneoplastic Syndromes | 2 | 2021 | 15 | 0.810 |
Why?
|
| Obesity Hypoventilation Syndrome | 1 | 2023 | 4 | 0.810 |
Why?
|
| Mydriasis | 2 | 2022 | 8 | 0.810 |
Why?
|
| Central Nervous System Vascular Malformations | 2 | 2022 | 19 | 0.810 |
Why?
|
| Pupil | 3 | 2023 | 47 | 0.810 |
Why?
|
| Vision Screening | 1 | 2023 | 8 | 0.800 |
Why?
|
| Corneal Diseases | 1 | 2024 | 94 | 0.800 |
Why?
|
| Scalp | 2 | 2021 | 58 | 0.800 |
Why?
|
| Syringomyelia | 1 | 2023 | 21 | 0.800 |
Why?
|
| Subclavian Steal Syndrome | 1 | 2023 | 6 | 0.800 |
Why?
|
| Retinal Detachment | 2 | 2021 | 42 | 0.800 |
Why?
|
| Amblyopia | 1 | 2023 | 34 | 0.790 |
Why?
|
| Electric Stimulation Therapy | 1 | 2024 | 85 | 0.790 |
Why?
|
| Ranibizumab | 1 | 2023 | 12 | 0.790 |
Why?
|
| Hydroxychloroquine | 1 | 2023 | 19 | 0.780 |
Why?
|
| Antifungal Agents | 2 | 2016 | 298 | 0.780 |
Why?
|
| Physiological Phenomena | 1 | 2023 | 3 | 0.780 |
Why?
|
| Aphasia | 1 | 2023 | 14 | 0.780 |
Why?
|
| Climate Change | 1 | 2024 | 64 | 0.780 |
Why?
|
| Sphenoid Sinusitis | 1 | 2022 | 1 | 0.770 |
Why?
|
| Collateral Circulation | 1 | 2023 | 41 | 0.770 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2023 | 51 | 0.770 |
Why?
|
| Lacrimal Apparatus Diseases | 2 | 2025 | 41 | 0.770 |
Why?
|
| Coloboma | 1 | 2023 | 41 | 0.770 |
Why?
|
| SEER Program | 1 | 2023 | 210 | 0.760 |
Why?
|
| Apraxias | 1 | 2022 | 16 | 0.760 |
Why?
|
| Tonic Pupil | 1 | 2022 | 4 | 0.760 |
Why?
|
| Subclavian Artery | 1 | 2023 | 65 | 0.760 |
Why?
|
| Zinc | 1 | 2023 | 128 | 0.760 |
Why?
|
| Arnold-Chiari Malformation | 1 | 2023 | 55 | 0.760 |
Why?
|
| Air Travel | 1 | 2022 | 2 | 0.760 |
Why?
|
| Amaurosis Fugax | 2 | 2022 | 3 | 0.750 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2023 | 64 | 0.750 |
Why?
|
| Migraine with Aura | 1 | 2022 | 17 | 0.750 |
Why?
|
| Glycogen Storage Disease Type V | 1 | 2022 | 2 | 0.750 |
Why?
|
| Agraphia | 1 | 2022 | 1 | 0.750 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2022 | 6 | 0.740 |
Why?
|
| Orbital Pseudotumor | 2 | 2019 | 8 | 0.740 |
Why?
|
| Papilloma, Choroid Plexus | 1 | 2022 | 1 | 0.740 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2020 | 103 | 0.740 |
Why?
|
| Encephalocele | 1 | 2023 | 65 | 0.740 |
Why?
|
| Retinopathy of Prematurity | 1 | 2023 | 64 | 0.740 |
Why?
|
| Hearing Loss, Bilateral | 2 | 2021 | 16 | 0.740 |
Why?
|
| Mucormycosis | 1 | 2022 | 31 | 0.740 |
Why?
|
| Retinal Artery | 1 | 2022 | 15 | 0.730 |
Why?
|
| Lymphoma, Follicular | 1 | 2022 | 32 | 0.730 |
Why?
|
| Retinitis Pigmentosa | 1 | 2023 | 89 | 0.730 |
Why?
|
| Cataract Extraction | 6 | 2011 | 129 | 0.730 |
Why?
|
| Rhabdomyolysis | 1 | 2022 | 35 | 0.730 |
Why?
|
| Astrocytes | 1 | 2025 | 288 | 0.720 |
Why?
|
| Cerebellar Ataxia | 1 | 2022 | 72 | 0.720 |
Why?
|
| Enterovirus A, Human | 1 | 2021 | 3 | 0.720 |
Why?
|
| Hand, Foot and Mouth Disease | 1 | 2021 | 3 | 0.720 |
Why?
|
| Cryopyrin-Associated Periodic Syndromes | 1 | 2021 | 3 | 0.710 |
Why?
|
| Fistula | 1 | 2022 | 52 | 0.710 |
Why?
|
| Eyelashes | 1 | 2021 | 3 | 0.710 |
Why?
|
| Hyperaldosteronism | 1 | 2021 | 18 | 0.710 |
Why?
|
| Calciphylaxis | 1 | 2021 | 3 | 0.710 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2022 | 63 | 0.710 |
Why?
|
| Dyslexia | 1 | 2022 | 31 | 0.710 |
Why?
|
| Cerebral Angiography | 6 | 2023 | 106 | 0.710 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2021 | 16 | 0.710 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2022 | 68 | 0.710 |
Why?
|
| Keratoconjunctivitis Sicca | 1 | 2022 | 50 | 0.700 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2018 | 164 | 0.700 |
Why?
|
| Fovea Centralis | 1 | 2021 | 7 | 0.700 |
Why?
|
| Patient Education as Topic | 1 | 2025 | 464 | 0.700 |
Why?
|
| Hematoma, Subdural, Chronic | 1 | 2021 | 13 | 0.690 |
Why?
|
| Xerophthalmia | 1 | 2021 | 8 | 0.690 |
Why?
|
| Brain Abscess | 1 | 2021 | 54 | 0.690 |
Why?
|
| Vitreous Hemorrhage | 2 | 2022 | 7 | 0.690 |
Why?
|
| Solanum tuberosum | 1 | 2021 | 12 | 0.690 |
Why?
|
| Pituitary ACTH Hypersecretion | 2 | 2021 | 9 | 0.690 |
Why?
|
| Perception | 1 | 2023 | 229 | 0.690 |
Why?
|
| Aneurysm, Ruptured | 1 | 2021 | 34 | 0.690 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2021 | 11 | 0.690 |
Why?
|
| Subarachnoid Space | 1 | 2021 | 24 | 0.690 |
Why?
|
| HELLP Syndrome | 1 | 2021 | 13 | 0.690 |
Why?
|
| Drug Costs | 1 | 2021 | 62 | 0.680 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2022 | 286 | 0.680 |
Why?
|
| Herpes Simplex | 1 | 2021 | 56 | 0.680 |
Why?
|
| Neurosyphilis | 1 | 2021 | 15 | 0.680 |
Why?
|
| Mesencephalon | 1 | 2021 | 39 | 0.680 |
Why?
|
| Acetylcholine Release Inhibitors | 1 | 2021 | 18 | 0.680 |
Why?
|
| Botulinum Toxins, Type A | 2 | 2021 | 165 | 0.670 |
Why?
|
| Meningitis | 1 | 2021 | 98 | 0.670 |
Why?
|
| Lacrimal Duct Obstruction | 1 | 2021 | 20 | 0.670 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2021 | 33 | 0.670 |
Why?
|
| Blast Injuries | 1 | 2021 | 58 | 0.670 |
Why?
|
| Hashimoto Disease | 1 | 2021 | 31 | 0.670 |
Why?
|
| Hematoma | 2 | 2016 | 90 | 0.670 |
Why?
|
| Arteriovenous Malformations | 1 | 2021 | 47 | 0.660 |
Why?
|
| Torsion Abnormality | 1 | 2020 | 29 | 0.660 |
Why?
|
| Tolosa-Hunt Syndrome | 2 | 2020 | 3 | 0.660 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 3 | 2021 | 182 | 0.660 |
Why?
|
| Craniotomy | 2 | 2020 | 102 | 0.650 |
Why?
|
| Wound Healing | 1 | 2024 | 476 | 0.650 |
Why?
|
| Doxycycline | 2 | 2019 | 115 | 0.650 |
Why?
|
| Extraterrestrial Environment | 4 | 2025 | 8 | 0.650 |
Why?
|
| Anatomic Landmarks | 1 | 2020 | 20 | 0.650 |
Why?
|
| Neurocysticercosis | 1 | 2020 | 25 | 0.650 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2020 | 20 | 0.650 |
Why?
|
| Posterior Cerebral Artery | 1 | 2020 | 6 | 0.640 |
Why?
|
| Neurodegenerative Diseases | 1 | 2023 | 288 | 0.640 |
Why?
|
| Hemangioma, Cavernous | 1 | 2020 | 19 | 0.640 |
Why?
|
| Maxilla | 1 | 2020 | 42 | 0.640 |
Why?
|
| Aneurysm | 1 | 2020 | 68 | 0.640 |
Why?
|
| Thiamine | 2 | 2019 | 10 | 0.640 |
Why?
|
| G(M1) Ganglioside | 2 | 2022 | 9 | 0.630 |
Why?
|
| Brain Infarction | 1 | 2020 | 28 | 0.630 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 81 | 0.630 |
Why?
|
| Awards and Prizes | 1 | 2020 | 63 | 0.620 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2023 | 236 | 0.620 |
Why?
|
| Quality Assurance, Health Care | 3 | 2009 | 210 | 0.620 |
Why?
|
| Comorbidity | 2 | 2024 | 1600 | 0.620 |
Why?
|
| Career Choice | 2 | 2014 | 162 | 0.620 |
Why?
|
| Myositis | 1 | 2021 | 106 | 0.620 |
Why?
|
| Temporal Lobe | 1 | 2020 | 116 | 0.610 |
Why?
|
| School Admission Criteria | 2 | 2011 | 29 | 0.610 |
Why?
|
| Vitamin B Complex | 1 | 2019 | 38 | 0.610 |
Why?
|
| Ataxia | 1 | 2021 | 169 | 0.600 |
Why?
|
| Decision Making | 1 | 2024 | 684 | 0.600 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2020 | 52 | 0.600 |
Why?
|
| Lacrimal Apparatus | 1 | 2021 | 126 | 0.600 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2019 | 13 | 0.600 |
Why?
|
| Cerebral Hemorrhage | 1 | 2020 | 153 | 0.600 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 313 | 0.590 |
Why?
|
| Retinal Vasculitis | 1 | 2018 | 2 | 0.590 |
Why?
|
| Cerebrospinal Fluid Shunts | 2 | 2022 | 98 | 0.590 |
Why?
|
| Malnutrition | 1 | 2021 | 156 | 0.590 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2019 | 23 | 0.590 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2018 | 8 | 0.590 |
Why?
|
| Transcriptome | 1 | 2026 | 1163 | 0.580 |
Why?
|
| Young Adult | 13 | 2026 | 10104 | 0.580 |
Why?
|
| Virtual Reality | 3 | 2023 | 34 | 0.580 |
Why?
|
| Jews | 1 | 2018 | 33 | 0.580 |
Why?
|
| Incidence | 6 | 2026 | 3347 | 0.580 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 245 | 0.570 |
Why?
|
| Siphonaptera | 1 | 2018 | 5 | 0.570 |
Why?
|
| Skin Neoplasms | 2 | 2023 | 904 | 0.570 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2017 | 226 | 0.570 |
Why?
|
| Glioblastoma | 1 | 2022 | 346 | 0.570 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2018 | 29 | 0.570 |
Why?
|
| Immunity, Innate | 1 | 2021 | 411 | 0.570 |
Why?
|
| Aquaporin 4 | 3 | 2025 | 15 | 0.560 |
Why?
|
| Vascular Neoplasms | 1 | 2018 | 32 | 0.560 |
Why?
|
| Periodicals as Topic | 4 | 2022 | 180 | 0.560 |
Why?
|
| Paraproteinemias | 1 | 2018 | 21 | 0.560 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 1277 | 0.560 |
Why?
|
| Leukemia | 1 | 2021 | 375 | 0.560 |
Why?
|
| Forecasting | 1 | 2019 | 361 | 0.550 |
Why?
|
| Thyroid Neoplasms | 1 | 2021 | 248 | 0.550 |
Why?
|
| Chronic Disease | 5 | 2025 | 1234 | 0.550 |
Why?
|
| Ethambutol | 1 | 2017 | 6 | 0.550 |
Why?
|
| Insect Bites and Stings | 1 | 2018 | 39 | 0.550 |
Why?
|
| Maxillary Artery | 1 | 2017 | 3 | 0.550 |
Why?
|
| Botulinum Toxins | 1 | 2019 | 125 | 0.540 |
Why?
|
| Carotid Artery, Internal | 3 | 2021 | 55 | 0.540 |
Why?
|
| Risk Factors | 11 | 2025 | 10959 | 0.530 |
Why?
|
| Optic Tract | 1 | 2017 | 2 | 0.530 |
Why?
|
| Dilatation | 3 | 2022 | 70 | 0.530 |
Why?
|
| Cerebellopontine Angle | 1 | 2017 | 10 | 0.520 |
Why?
|
| Technology | 5 | 2023 | 69 | 0.520 |
Why?
|
| Lipoprotein(a) | 1 | 2018 | 135 | 0.520 |
Why?
|
| Veins | 1 | 2017 | 99 | 0.520 |
Why?
|
| Transgender Persons | 1 | 2018 | 68 | 0.520 |
Why?
|
| Ovarian Neoplasms | 1 | 2021 | 455 | 0.520 |
Why?
|
| Graft Rejection | 1 | 2021 | 560 | 0.520 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.520 |
Why?
|
| Disease Progression | 5 | 2023 | 2206 | 0.510 |
Why?
|
| Arteriovenous Fistula | 1 | 2017 | 55 | 0.510 |
Why?
|
| Vaccines | 1 | 2022 | 384 | 0.510 |
Why?
|
| Adaptation, Physiological | 3 | 2024 | 261 | 0.510 |
Why?
|
| Central Serous Chorioretinopathy | 1 | 2016 | 5 | 0.510 |
Why?
|
| Retrobulbar Hemorrhage | 1 | 2016 | 1 | 0.510 |
Why?
|
| Tuberculin Test | 1 | 2017 | 120 | 0.510 |
Why?
|
| Blood Pressure | 3 | 2021 | 1344 | 0.500 |
Why?
|
| Hemifacial Spasm | 1 | 2016 | 15 | 0.500 |
Why?
|
| Granuloma Annulare | 1 | 2016 | 2 | 0.500 |
Why?
|
| Jehovah's Witnesses | 1 | 2016 | 17 | 0.500 |
Why?
|
| Internet | 3 | 2024 | 422 | 0.500 |
Why?
|
| Specialization | 1 | 2017 | 75 | 0.500 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2016 | 25 | 0.500 |
Why?
|
| Aging | 1 | 2024 | 1264 | 0.500 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 454 | 0.500 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2025 | 613 | 0.490 |
Why?
|
| Laser Coagulation | 5 | 2023 | 109 | 0.490 |
Why?
|
| Latent Tuberculosis | 1 | 2017 | 76 | 0.490 |
Why?
|
| Interferon-gamma Release Tests | 1 | 2017 | 89 | 0.490 |
Why?
|
| Plasmacytoma | 1 | 2016 | 10 | 0.490 |
Why?
|
| Melanoma | 1 | 2023 | 920 | 0.490 |
Why?
|
| Brain Ischemia | 2 | 2017 | 261 | 0.490 |
Why?
|
| Astrocytoma | 1 | 2017 | 102 | 0.490 |
Why?
|
| Uveitis | 1 | 2016 | 33 | 0.490 |
Why?
|
| Nerve Fibers | 4 | 2017 | 69 | 0.480 |
Why?
|
| Aspergillosis | 1 | 2016 | 46 | 0.480 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2016 | 34 | 0.480 |
Why?
|
| Sildenafil Citrate | 1 | 2016 | 57 | 0.480 |
Why?
|
| Lung Transplantation | 1 | 2020 | 350 | 0.480 |
Why?
|
| Search Engine | 3 | 2024 | 10 | 0.480 |
Why?
|
| Cooperative Behavior | 1 | 2017 | 223 | 0.470 |
Why?
|
| Interprofessional Relations | 1 | 2017 | 152 | 0.470 |
Why?
|
| Health Services Needs and Demand | 1 | 2017 | 169 | 0.470 |
Why?
|
| Evidence-Based Medicine | 4 | 2025 | 644 | 0.470 |
Why?
|
| Blood Sedimentation | 5 | 2021 | 26 | 0.470 |
Why?
|
| Propensity Score | 3 | 2025 | 265 | 0.460 |
Why?
|
| Vaccination | 1 | 2021 | 1040 | 0.460 |
Why?
|
| Antigens, Bacterial | 1 | 2017 | 320 | 0.460 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2020 | 274 | 0.460 |
Why?
|
| Antitubercular Agents | 1 | 2017 | 265 | 0.460 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 366 | 0.460 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 890 | 0.450 |
Why?
|
| Surveys and Questionnaires | 12 | 2023 | 4047 | 0.450 |
Why?
|
| Hypotension | 1 | 2017 | 185 | 0.450 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 378 | 0.450 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1169 | 0.450 |
Why?
|
| Fatal Outcome | 6 | 2018 | 364 | 0.450 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 632 | 0.450 |
Why?
|
| Case-Control Studies | 8 | 2021 | 3454 | 0.450 |
Why?
|
| Craniocerebral Trauma | 1 | 2016 | 141 | 0.440 |
Why?
|
| Recurrence | 5 | 2021 | 1483 | 0.440 |
Why?
|
| Afterimage | 1 | 2014 | 1 | 0.440 |
Why?
|
| Illusions | 1 | 2014 | 7 | 0.430 |
Why?
|
| Nerve Block | 2 | 2016 | 62 | 0.430 |
Why?
|
| Weightlessness Countermeasures | 2 | 2024 | 6 | 0.430 |
Why?
|
| Cryptococcosis | 1 | 2014 | 40 | 0.430 |
Why?
|
| Parkinson Disease | 1 | 2021 | 725 | 0.430 |
Why?
|
| Heart Transplantation | 1 | 2021 | 832 | 0.430 |
Why?
|
| Treatment Outcome | 9 | 2023 | 12984 | 0.430 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2016 | 113 | 0.430 |
Why?
|
| Cosmic Radiation | 2 | 2024 | 13 | 0.430 |
Why?
|
| Rod Opsins | 1 | 2014 | 17 | 0.420 |
Why?
|
| Optic Nerve Injuries | 1 | 2014 | 10 | 0.420 |
Why?
|
| Gangliosides | 1 | 2014 | 74 | 0.420 |
Why?
|
| Adrenoleukodystrophy | 2 | 2018 | 12 | 0.420 |
Why?
|
| Carotid Artery Injuries | 1 | 2013 | 35 | 0.410 |
Why?
|
| Cerebellar Neoplasms | 1 | 2017 | 320 | 0.410 |
Why?
|
| Steroids | 2 | 2015 | 172 | 0.410 |
Why?
|
| Vision, Low | 2 | 2017 | 12 | 0.410 |
Why?
|
| Decompression, Surgical | 3 | 2021 | 89 | 0.410 |
Why?
|
| Intravitreal Injections | 2 | 2024 | 40 | 0.410 |
Why?
|
| Angiography | 3 | 2023 | 188 | 0.410 |
Why?
|
| Academic Medical Centers | 3 | 2021 | 322 | 0.400 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2020 | 338 | 0.400 |
Why?
|
| Mutation | 7 | 2023 | 6177 | 0.400 |
Why?
|
| Peer Review, Health Care | 2 | 2003 | 15 | 0.400 |
Why?
|
| Rare Diseases | 3 | 2022 | 208 | 0.400 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2017 | 423 | 0.390 |
Why?
|
| Expert Testimony | 2 | 2003 | 36 | 0.390 |
Why?
|
| Combined Modality Therapy | 5 | 2021 | 1260 | 0.390 |
Why?
|
| Pregnancy | 7 | 2023 | 7572 | 0.390 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2017 | 314 | 0.390 |
Why?
|
| Anti-Bacterial Agents | 5 | 2025 | 2567 | 0.390 |
Why?
|
| Diagnostic Imaging | 2 | 2025 | 300 | 0.390 |
Why?
|
| Brain Diseases | 3 | 2019 | 305 | 0.390 |
Why?
|
| Breast Neoplasms | 2 | 2025 | 2648 | 0.380 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 2082 | 0.380 |
Why?
|
| Oculomotor Nerve | 2 | 2020 | 6 | 0.380 |
Why?
|
| Cat-Scratch Disease | 1 | 2012 | 28 | 0.370 |
Why?
|
| Myelin Sheath | 1 | 2013 | 127 | 0.370 |
Why?
|
| Thymectomy | 2 | 2022 | 24 | 0.370 |
Why?
|
| Spasm | 2 | 2020 | 46 | 0.370 |
Why?
|
| Positron-Emission Tomography | 4 | 2025 | 295 | 0.370 |
Why?
|
| Paralysis | 2 | 2022 | 29 | 0.360 |
Why?
|
| Adolescent | 10 | 2026 | 20982 | 0.360 |
Why?
|
| Eye Neoplasms | 2 | 2025 | 38 | 0.360 |
Why?
|
| Rickettsia typhi | 1 | 2011 | 12 | 0.360 |
Why?
|
| Fasciitis, Necrotizing | 2 | 2025 | 29 | 0.360 |
Why?
|
| Burkitt Lymphoma | 2 | 2004 | 134 | 0.350 |
Why?
|
| Radiculopathy | 1 | 2011 | 6 | 0.350 |
Why?
|
| Triamcinolone Acetonide | 1 | 2011 | 20 | 0.340 |
Why?
|
| Methylprednisolone | 3 | 2021 | 97 | 0.340 |
Why?
|
| Hypertension, Pulmonary | 1 | 2016 | 463 | 0.340 |
Why?
|
| Societies, Medical | 6 | 2025 | 794 | 0.330 |
Why?
|
| Orbital Neoplasms | 3 | 2017 | 49 | 0.330 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 578 | 0.320 |
Why?
|
| Corpus Callosum | 2 | 2022 | 106 | 0.320 |
Why?
|
| Ciliary Arteries | 2 | 2022 | 2 | 0.320 |
Why?
|
| Prognosis | 7 | 2025 | 4952 | 0.320 |
Why?
|
| Personnel Selection | 1 | 2011 | 79 | 0.320 |
Why?
|
| Vitreous Body | 3 | 2022 | 56 | 0.310 |
Why?
|
| Immunoglobulin G | 4 | 2019 | 810 | 0.310 |
Why?
|
| Drug Therapy, Combination | 8 | 2016 | 1170 | 0.310 |
Why?
|
| Oxidative Stress | 2 | 2025 | 807 | 0.300 |
Why?
|
| Benchmarking | 3 | 2015 | 138 | 0.300 |
Why?
|
| Ischemia | 2 | 2017 | 355 | 0.290 |
Why?
|
| Child | 12 | 2026 | 26299 | 0.290 |
Why?
|
| Phacoemulsification | 3 | 2025 | 132 | 0.290 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2019 | 147 | 0.290 |
Why?
|
| Mitochondria | 2 | 2024 | 759 | 0.290 |
Why?
|
| Program Evaluation | 6 | 2009 | 441 | 0.280 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 303 | 0.280 |
Why?
|
| Lymphoma, AIDS-Related | 2 | 2013 | 27 | 0.280 |
Why?
|
| Time Factors | 6 | 2023 | 6279 | 0.280 |
Why?
|
| Models, Educational | 1 | 2008 | 75 | 0.280 |
Why?
|
| Macular Edema | 2 | 2026 | 27 | 0.270 |
Why?
|
| Specialty Boards | 2 | 2006 | 25 | 0.270 |
Why?
|
| Emergencies | 2 | 2023 | 180 | 0.270 |
Why?
|
| Eye Protective Devices | 2 | 2025 | 11 | 0.270 |
Why?
|
| Evoked Potentials, Visual | 2 | 2017 | 33 | 0.270 |
Why?
|
| Vitrectomy | 2 | 2022 | 41 | 0.270 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 3413 | 0.260 |
Why?
|
| Reproducibility of Results | 8 | 2023 | 2989 | 0.260 |
Why?
|
| Genetic Therapy | 2 | 2022 | 726 | 0.260 |
Why?
|
| Risk Assessment | 4 | 2025 | 3695 | 0.260 |
Why?
|
| Recovery of Function | 2 | 2021 | 456 | 0.260 |
Why?
|
| Biopsy, Needle | 2 | 2019 | 216 | 0.260 |
Why?
|
| Child, Preschool | 6 | 2026 | 15057 | 0.250 |
Why?
|
| Laminectomy | 1 | 2006 | 24 | 0.250 |
Why?
|
| Fructose | 1 | 2007 | 61 | 0.250 |
Why?
|
| Laboratories | 1 | 2007 | 84 | 0.250 |
Why?
|
| Professional Competence | 1 | 2007 | 94 | 0.250 |
Why?
|
| Prone Position | 1 | 2006 | 32 | 0.250 |
Why?
|
| Delphi Technique | 2 | 2025 | 262 | 0.240 |
Why?
|
| Hindlimb Suspension | 1 | 2026 | 14 | 0.240 |
Why?
|
| Antibodies, Bacterial | 2 | 2011 | 427 | 0.240 |
Why?
|
| Facial Pain | 1 | 2005 | 9 | 0.240 |
Why?
|
| Head-Down Tilt | 2 | 2024 | 26 | 0.240 |
Why?
|
| Cost-Benefit Analysis | 2 | 2021 | 543 | 0.240 |
Why?
|
| Education, Medical, Continuing | 2 | 2007 | 133 | 0.240 |
Why?
|
| Bacteroidaceae Infections | 1 | 2025 | 2 | 0.240 |
Why?
|
| Endovascular Procedures | 1 | 2014 | 766 | 0.230 |
Why?
|
| Group Processes | 1 | 2006 | 48 | 0.230 |
Why?
|
| Prevotella | 1 | 2025 | 10 | 0.230 |
Why?
|
| Writing | 2 | 2023 | 60 | 0.230 |
Why?
|
| Optic Disk Drusen | 1 | 2005 | 3 | 0.230 |
Why?
|
| Geniculate Bodies | 1 | 2025 | 10 | 0.230 |
Why?
|
| Furosemide | 2 | 2006 | 35 | 0.230 |
Why?
|
| Perceptual Disorders | 1 | 2025 | 4 | 0.230 |
Why?
|
| Administration, Oral | 2 | 2019 | 709 | 0.230 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2005 | 53 | 0.230 |
Why?
|
| Hypergravity | 1 | 2025 | 2 | 0.230 |
Why?
|
| Republic of Korea | 1 | 2025 | 56 | 0.230 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2025 | 9 | 0.230 |
Why?
|
| Stents | 3 | 2021 | 778 | 0.220 |
Why?
|
| Sex Distribution | 1 | 2026 | 322 | 0.220 |
Why?
|
| Osteoporosis | 1 | 2006 | 134 | 0.220 |
Why?
|
| Age Distribution | 1 | 2026 | 429 | 0.220 |
Why?
|
| C-Reactive Protein | 3 | 2021 | 455 | 0.220 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2025 | 59 | 0.220 |
Why?
|
| Scleral Buckling | 2 | 2018 | 3 | 0.220 |
Why?
|
| Necrosis | 2 | 2025 | 195 | 0.220 |
Why?
|
| Quantum Theory | 1 | 2024 | 19 | 0.220 |
Why?
|
| Cogan Syndrome | 1 | 2024 | 1 | 0.220 |
Why?
|
| Diuretics | 2 | 2006 | 158 | 0.220 |
Why?
|
| Intracranial Embolism | 1 | 2004 | 25 | 0.210 |
Why?
|
| Endophthalmitis | 1 | 2004 | 49 | 0.210 |
Why?
|
| Outpatients | 1 | 2006 | 266 | 0.210 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2004 | 251 | 0.210 |
Why?
|
| Bed Rest | 1 | 2024 | 24 | 0.210 |
Why?
|
| Infrared Rays | 1 | 2024 | 23 | 0.210 |
Why?
|
| Corneal Perforation | 1 | 2024 | 1 | 0.210 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2024 | 41 | 0.210 |
Why?
|
| Prednisone | 3 | 2021 | 244 | 0.210 |
Why?
|
| Printing, Three-Dimensional | 1 | 2025 | 88 | 0.210 |
Why?
|
| Exophthalmos | 3 | 2018 | 31 | 0.210 |
Why?
|
| Vision, Monocular | 1 | 2024 | 5 | 0.210 |
Why?
|
| Periosteum | 1 | 2004 | 32 | 0.210 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2025 | 100 | 0.210 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2005 | 110 | 0.210 |
Why?
|
| Biophysics | 1 | 2024 | 49 | 0.210 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2004 | 14 | 0.210 |
Why?
|
| Myotonia | 1 | 2004 | 2 | 0.210 |
Why?
|
| DNA, Mitochondrial | 2 | 2022 | 241 | 0.210 |
Why?
|
| Hydrodynamics | 1 | 2024 | 28 | 0.210 |
Why?
|
| Slit Lamp Microscopy | 2 | 2021 | 4 | 0.210 |
Why?
|
| Information Services | 1 | 2004 | 23 | 0.210 |
Why?
|
| Phototherapy | 1 | 2024 | 37 | 0.210 |
Why?
|
| Electric Impedance | 1 | 2024 | 72 | 0.210 |
Why?
|
| Hyponatremia | 1 | 2025 | 74 | 0.210 |
Why?
|
| California | 2 | 2020 | 128 | 0.210 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2023 | 165 | 0.210 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2024 | 39 | 0.210 |
Why?
|
| Radiology | 1 | 2025 | 126 | 0.210 |
Why?
|
| Neurologists | 1 | 2024 | 25 | 0.210 |
Why?
|
| Lymphocytosis | 1 | 2003 | 15 | 0.210 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2023 | 62 | 0.200 |
Why?
|
| Optometry | 1 | 2023 | 7 | 0.200 |
Why?
|
| Chlamydophila Infections | 1 | 2003 | 3 | 0.200 |
Why?
|
| Arthritis, Infectious | 1 | 2004 | 68 | 0.200 |
Why?
|
| Prothrombin | 1 | 2023 | 24 | 0.200 |
Why?
|
| Streptococcus agalactiae | 1 | 2004 | 102 | 0.200 |
Why?
|
| Algorithms | 3 | 2025 | 1686 | 0.200 |
Why?
|
| Advisory Committees | 1 | 2004 | 147 | 0.200 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2003 | 10 | 0.200 |
Why?
|
| Tertiary Care Centers | 1 | 2024 | 251 | 0.200 |
Why?
|
| Checklist | 1 | 2024 | 101 | 0.200 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2003 | 20 | 0.200 |
Why?
|
| Prevalence | 4 | 2020 | 2694 | 0.200 |
Why?
|
| Journalism, Medical | 1 | 2003 | 8 | 0.200 |
Why?
|
| Radiation Exposure | 1 | 2023 | 43 | 0.200 |
Why?
|
| Carbon Dioxide | 1 | 2024 | 272 | 0.200 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 89 | 0.200 |
Why?
|
| Cadaver | 2 | 2020 | 121 | 0.200 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2024 | 157 | 0.200 |
Why?
|
| Endothelial Growth Factors | 1 | 2023 | 40 | 0.200 |
Why?
|
| Guidelines as Topic | 4 | 2009 | 200 | 0.200 |
Why?
|
| Ephedra | 1 | 2002 | 1 | 0.200 |
Why?
|
| Cerebral Revascularization | 1 | 2023 | 22 | 0.200 |
Why?
|
| Drug Hypersensitivity | 1 | 2004 | 97 | 0.200 |
Why?
|
| Whipple Disease | 1 | 2002 | 5 | 0.190 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2023 | 54 | 0.190 |
Why?
|
| Prospective Studies | 5 | 2021 | 6494 | 0.190 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2023 | 36 | 0.190 |
Why?
|
| Single-Blind Method | 3 | 2021 | 241 | 0.190 |
Why?
|
| Actinobacteria | 1 | 2002 | 11 | 0.190 |
Why?
|
| Problem-Based Learning | 1 | 2004 | 82 | 0.190 |
Why?
|
| Actinomycetales Infections | 1 | 2002 | 14 | 0.190 |
Why?
|
| Pain | 1 | 2005 | 439 | 0.190 |
Why?
|
| Bevacizumab | 1 | 2023 | 60 | 0.190 |
Why?
|
| Erectile Dysfunction | 1 | 2005 | 196 | 0.190 |
Why?
|
| Pilot Projects | 2 | 2024 | 1454 | 0.190 |
Why?
|
| Ubiquinone | 1 | 2022 | 27 | 0.190 |
Why?
|
| Blepharoptosis | 2 | 2019 | 68 | 0.190 |
Why?
|
| Natural Language Processing | 1 | 2023 | 75 | 0.190 |
Why?
|
| Retinal Hemorrhage | 2 | 2021 | 18 | 0.190 |
Why?
|
| Lasers | 1 | 2023 | 114 | 0.190 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 76 | 0.190 |
Why?
|
| Video Recording | 1 | 2024 | 208 | 0.190 |
Why?
|
| Methotrexate | 4 | 2016 | 342 | 0.190 |
Why?
|
| Carotid Arteries | 1 | 2023 | 126 | 0.190 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2022 | 114 | 0.190 |
Why?
|
| Patient Selection | 2 | 2020 | 726 | 0.190 |
Why?
|
| Facial Nerve | 1 | 2022 | 25 | 0.190 |
Why?
|
| Animals | 5 | 2025 | 34374 | 0.180 |
Why?
|
| Fourth Ventricle | 1 | 2022 | 9 | 0.180 |
Why?
|
| Abducens Nerve | 1 | 2021 | 3 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2023 | 81 | 0.180 |
Why?
|
| Arteritis | 1 | 2021 | 7 | 0.180 |
Why?
|
| Hypertension, Malignant | 1 | 2002 | 7 | 0.180 |
Why?
|
| Encephalomyelitis, Acute Disseminated | 1 | 2022 | 10 | 0.180 |
Why?
|
| Disability Evaluation | 1 | 2003 | 197 | 0.180 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2024 | 260 | 0.180 |
Why?
|
| Radiotherapy | 2 | 2018 | 120 | 0.180 |
Why?
|
| Carotid Stenosis | 1 | 2023 | 106 | 0.180 |
Why?
|
| Aircraft | 1 | 2002 | 22 | 0.180 |
Why?
|
| Gadolinium | 1 | 2022 | 112 | 0.180 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2023 | 111 | 0.180 |
Why?
|
| Ascorbic Acid | 1 | 2022 | 71 | 0.180 |
Why?
|
| Geriatric Assessment | 1 | 2003 | 186 | 0.180 |
Why?
|
| Medicine | 1 | 2023 | 102 | 0.180 |
Why?
|
| Hydroxyethylrutoside | 1 | 2021 | 1 | 0.180 |
Why?
|
| Hematoma, Subdural | 1 | 2021 | 28 | 0.180 |
Why?
|
| Streptococcal Infections | 1 | 2004 | 248 | 0.180 |
Why?
|
| Placebos | 1 | 2022 | 227 | 0.180 |
Why?
|
| Herpesvirus 2, Human | 1 | 2021 | 14 | 0.180 |
Why?
|
| Antihypertensive Agents | 1 | 2025 | 422 | 0.180 |
Why?
|
| Cranial Nerves | 1 | 2021 | 21 | 0.180 |
Why?
|
| Feeding and Eating Disorders | 1 | 2022 | 74 | 0.180 |
Why?
|
| Information Dissemination | 1 | 2024 | 195 | 0.180 |
Why?
|
| DNA Damage | 1 | 2025 | 527 | 0.180 |
Why?
|
| Thrombosis | 1 | 2006 | 495 | 0.180 |
Why?
|
| Vitamins | 1 | 2022 | 115 | 0.180 |
Why?
|
| Gasoline | 1 | 2021 | 4 | 0.180 |
Why?
|
| Meningeal Arteries | 1 | 2021 | 15 | 0.180 |
Why?
|
| Carotid Artery, Common | 1 | 2021 | 60 | 0.180 |
Why?
|
| Keratomileusis, Laser In Situ | 1 | 2002 | 84 | 0.170 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2023 | 220 | 0.170 |
Why?
|
| Mastectomy | 1 | 2021 | 75 | 0.170 |
Why?
|
| Point-of-Care Systems | 1 | 2024 | 206 | 0.170 |
Why?
|
| Carbon Monoxide | 1 | 2021 | 26 | 0.170 |
Why?
|
| Consensus | 1 | 2024 | 565 | 0.170 |
Why?
|
| Communicable Disease Control | 1 | 2023 | 141 | 0.170 |
Why?
|
| Hemorrhage | 2 | 2021 | 498 | 0.170 |
Why?
|
| Visual Cortex | 1 | 2003 | 121 | 0.170 |
Why?
|
| Vena Cava, Superior | 1 | 2021 | 58 | 0.170 |
Why?
|
| Emergency Treatment | 1 | 2002 | 85 | 0.170 |
Why?
|
| Wearable Electronic Devices | 1 | 2023 | 116 | 0.170 |
Why?
|
| Seoul | 1 | 2021 | 1 | 0.170 |
Why?
|
| Injections, Intraocular | 1 | 2021 | 7 | 0.170 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2023 | 210 | 0.170 |
Why?
|
| Liver Diseases | 1 | 2025 | 381 | 0.170 |
Why?
|
| Injections, Intradermal | 1 | 2021 | 29 | 0.170 |
Why?
|
| Pedigree | 2 | 2021 | 1710 | 0.170 |
Why?
|
| Developing Countries | 1 | 2023 | 304 | 0.170 |
Why?
|
| Cough | 1 | 2021 | 99 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 341 | 0.170 |
Why?
|
| Sleep | 1 | 2024 | 373 | 0.170 |
Why?
|
| Self Report | 1 | 2024 | 563 | 0.170 |
Why?
|
| Infant | 5 | 2026 | 13306 | 0.170 |
Why?
|
| Publications | 1 | 2020 | 36 | 0.170 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 475 | 0.160 |
Why?
|
| Sphenoid Sinus | 1 | 2020 | 10 | 0.160 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2002 | 95 | 0.160 |
Why?
|
| Infusions, Intravenous | 2 | 2021 | 549 | 0.160 |
Why?
|
| User-Computer Interface | 3 | 2023 | 161 | 0.160 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 42 | 0.160 |
Why?
|
| Survival Rate | 1 | 2025 | 2151 | 0.160 |
Why?
|
| Efficiency, Organizational | 1 | 2020 | 58 | 0.160 |
Why?
|
| Heart Diseases | 2 | 2002 | 505 | 0.160 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2023 | 694 | 0.160 |
Why?
|
| Remote Consultation | 1 | 2020 | 26 | 0.160 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2021 | 43 | 0.160 |
Why?
|
| Neuroendoscopy | 1 | 2020 | 32 | 0.160 |
Why?
|
| ROC Curve | 3 | 2025 | 615 | 0.160 |
Why?
|
| Immunosuppressive Agents | 3 | 2021 | 667 | 0.160 |
Why?
|
| Pregnancy Outcome | 2 | 2019 | 630 | 0.160 |
Why?
|
| Cognition Disorders | 2 | 2011 | 565 | 0.160 |
Why?
|
| Oxygen | 1 | 2023 | 552 | 0.160 |
Why?
|
| Eyelids | 1 | 2021 | 108 | 0.160 |
Why?
|
| Hematocrit | 1 | 2020 | 108 | 0.160 |
Why?
|
| Professionalism | 1 | 2020 | 45 | 0.160 |
Why?
|
| Frontal Lobe | 1 | 2020 | 116 | 0.160 |
Why?
|
| Aortic Diseases | 1 | 2002 | 189 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 131 | 0.160 |
Why?
|
| Dysgerminoma | 1 | 2019 | 4 | 0.160 |
Why?
|
| Infant, Newborn | 3 | 2023 | 8589 | 0.160 |
Why?
|
| Brain Edema | 1 | 2020 | 65 | 0.150 |
Why?
|
| Rotation | 1 | 2019 | 40 | 0.150 |
Why?
|
| Infusions, Parenteral | 1 | 2019 | 78 | 0.150 |
Why?
|
| Meningoencephalitis | 1 | 2019 | 20 | 0.150 |
Why?
|
| Anisocoria | 1 | 2019 | 6 | 0.150 |
Why?
|
| Antineoplastic Agents | 2 | 2022 | 1810 | 0.150 |
Why?
|
| Toothache | 1 | 2019 | 2 | 0.150 |
Why?
|
| Medicare | 1 | 2023 | 437 | 0.150 |
Why?
|
| Glycopyrrolate | 1 | 2019 | 10 | 0.150 |
Why?
|
| Hyperhidrosis | 1 | 2019 | 9 | 0.150 |
Why?
|
| Arteries | 1 | 2020 | 210 | 0.150 |
Why?
|
| Skin Diseases | 1 | 2021 | 141 | 0.150 |
Why?
|
| Reference Standards | 1 | 2020 | 231 | 0.150 |
Why?
|
| Demyelinating Diseases | 1 | 2019 | 68 | 0.150 |
Why?
|
| Keratitis | 1 | 2020 | 105 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1356 | 0.150 |
Why?
|
| Secondary Prevention | 1 | 2020 | 220 | 0.150 |
Why?
|
| Ear Diseases | 1 | 2019 | 23 | 0.150 |
Why?
|
| Cavernous Sinus Thrombosis | 1 | 2018 | 7 | 0.150 |
Why?
|
| Blast Crisis | 1 | 2018 | 17 | 0.150 |
Why?
|
| Aspirin | 1 | 2020 | 216 | 0.150 |
Why?
|
| Cholinergic Antagonists | 1 | 2019 | 47 | 0.150 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 1610 | 0.150 |
Why?
|
| Research | 1 | 2020 | 266 | 0.150 |
Why?
|
| Pre-Eclampsia | 1 | 2021 | 223 | 0.140 |
Why?
|
| Gestational Age | 1 | 2023 | 1221 | 0.140 |
Why?
|
| Tobacco Use Disorder | 1 | 2019 | 90 | 0.140 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 713 | 0.140 |
Why?
|
| Cellulitis | 1 | 2018 | 62 | 0.140 |
Why?
|
| Immune System Diseases | 1 | 2019 | 52 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2023 | 617 | 0.140 |
Why?
|
| Attitude of Health Personnel | 3 | 2021 | 714 | 0.140 |
Why?
|
| Carrier State | 1 | 2018 | 80 | 0.140 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2018 | 36 | 0.140 |
Why?
|
| Cerebrospinal Fluid | 2 | 2016 | 101 | 0.140 |
Why?
|
| Ophthalmoscopy | 1 | 2018 | 31 | 0.140 |
Why?
|
| Carcinoma, Basosquamous | 1 | 2017 | 1 | 0.140 |
Why?
|
| Dementia | 1 | 2003 | 433 | 0.140 |
Why?
|
| Quality of Health Care | 4 | 2006 | 411 | 0.140 |
Why?
|
| Meningocele | 1 | 2017 | 18 | 0.130 |
Why?
|
| Functional Laterality | 2 | 2015 | 183 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2026 | 1413 | 0.130 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 3834 | 0.130 |
Why?
|
| Liver | 1 | 2025 | 1799 | 0.130 |
Why?
|
| Nose Neoplasms | 1 | 2017 | 31 | 0.130 |
Why?
|
| Polychondritis, Relapsing | 1 | 2017 | 4 | 0.130 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 91 | 0.130 |
Why?
|
| Quality of Life | 2 | 2023 | 2117 | 0.130 |
Why?
|
| Peripheral Nerves | 1 | 2017 | 88 | 0.130 |
Why?
|
| Immunophenotyping | 1 | 2018 | 336 | 0.130 |
Why?
|
| Foundations | 1 | 2017 | 23 | 0.130 |
Why?
|
| Hydrogels | 1 | 2018 | 101 | 0.130 |
Why?
|
| Infant, Premature | 1 | 2023 | 856 | 0.130 |
Why?
|
| Genotype | 1 | 2023 | 2655 | 0.130 |
Why?
|
| Membrane Proteins | 3 | 1994 | 1613 | 0.130 |
Why?
|
| Accidents, Traffic | 1 | 2017 | 105 | 0.130 |
Why?
|
| Alcoholism | 1 | 2019 | 246 | 0.130 |
Why?
|
| Hypophysectomy | 1 | 2016 | 21 | 0.130 |
Why?
|
| Facial Muscles | 1 | 2016 | 26 | 0.130 |
Why?
|
| Bone Marrow | 1 | 2018 | 314 | 0.130 |
Why?
|
| Behcet Syndrome | 2 | 2015 | 14 | 0.130 |
Why?
|
| Calcium Channels, Q-Type | 1 | 2016 | 8 | 0.130 |
Why?
|
| Calcium Channels, P-Type | 1 | 2016 | 9 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2013 | 775 | 0.130 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2016 | 64 | 0.130 |
Why?
|
| Convergence, Ocular | 1 | 2016 | 2 | 0.130 |
Why?
|
| Lidocaine | 1 | 2016 | 41 | 0.120 |
Why?
|
| Adenocarcinoma | 2 | 2017 | 1000 | 0.120 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2016 | 45 | 0.120 |
Why?
|
| Inflammation | 1 | 2024 | 1492 | 0.120 |
Why?
|
| Antigens, CD | 1 | 2018 | 418 | 0.120 |
Why?
|
| Iris | 1 | 2016 | 36 | 0.120 |
Why?
|
| Treatment Refusal | 1 | 2016 | 78 | 0.120 |
Why?
|
| Alzheimer Disease | 1 | 2004 | 875 | 0.120 |
Why?
|
| Membrane Lipids | 2 | 1994 | 31 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 759 | 0.120 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2015 | 11 | 0.120 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2015 | 8 | 0.120 |
Why?
|
| Retinal Vein | 1 | 2015 | 5 | 0.120 |
Why?
|
| Anesthetics, Local | 1 | 2016 | 85 | 0.120 |
Why?
|
| Equipment Design | 1 | 2017 | 555 | 0.120 |
Why?
|
| Dermatomyositis | 1 | 2015 | 34 | 0.120 |
Why?
|
| Blood Loss, Surgical | 1 | 2016 | 169 | 0.120 |
Why?
|
| Proton Therapy | 1 | 2017 | 157 | 0.110 |
Why?
|
| Chemoradiotherapy | 1 | 2016 | 120 | 0.110 |
Why?
|
| Health Surveys | 2 | 2009 | 263 | 0.110 |
Why?
|
| Adenine | 1 | 2016 | 124 | 0.110 |
Why?
|
| Clonidine | 1 | 2015 | 30 | 0.110 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2015 | 36 | 0.110 |
Why?
|
| Cryptococcus gattii | 1 | 2014 | 2 | 0.110 |
Why?
|
| Spectrometry, Fluorescence | 3 | 1994 | 79 | 0.110 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 1 | 2015 | 26 | 0.110 |
Why?
|
| Flucytosine | 1 | 2014 | 10 | 0.110 |
Why?
|
| Hearing Loss | 1 | 2017 | 210 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 234 | 0.110 |
Why?
|
| Antibodies, Fungal | 1 | 2014 | 13 | 0.110 |
Why?
|
| Cryptococcus neoformans | 1 | 2014 | 21 | 0.110 |
Why?
|
| Antigens, Fungal | 1 | 2014 | 34 | 0.110 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 236 | 0.110 |
Why?
|
| Blood Transfusion | 1 | 2016 | 290 | 0.110 |
Why?
|
| Amphotericin B | 1 | 2014 | 90 | 0.110 |
Why?
|
| Global Health | 3 | 2021 | 632 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2016 | 187 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 865 | 0.110 |
Why?
|
| Diet | 1 | 2021 | 1121 | 0.110 |
Why?
|
| Piperidines | 1 | 2016 | 232 | 0.100 |
Why?
|
| Immunotherapy | 1 | 2019 | 765 | 0.100 |
Why?
|
| Colonic Neoplasms | 1 | 2017 | 265 | 0.100 |
Why?
|
| Third Ventricle | 1 | 2014 | 32 | 0.100 |
Why?
|
| Vestibular Diseases | 1 | 2015 | 66 | 0.100 |
Why?
|
| Olfaction Disorders | 1 | 2014 | 28 | 0.100 |
Why?
|
| Depression | 1 | 2003 | 1350 | 0.100 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2013 | 45 | 0.100 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2011 | 302 | 0.100 |
Why?
|
| Tremor | 1 | 2015 | 132 | 0.100 |
Why?
|
| Cysts | 1 | 2014 | 93 | 0.100 |
Why?
|
| Cocaine | 1 | 2015 | 209 | 0.100 |
Why?
|
| Phospholipids | 1 | 1994 | 103 | 0.100 |
Why?
|
| Computer Simulation | 3 | 2024 | 685 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2016 | 358 | 0.100 |
Why?
|
| Herpes Zoster Ophthalmicus | 1 | 2012 | 11 | 0.100 |
Why?
|
| Atrophy | 2 | 2004 | 251 | 0.100 |
Why?
|
| Bartonella henselae | 1 | 2012 | 16 | 0.100 |
Why?
|
| International Agencies | 1 | 2012 | 29 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2016 | 443 | 0.090 |
Why?
|
| Azithromycin | 1 | 2012 | 45 | 0.090 |
Why?
|
| Brain Injuries | 1 | 2017 | 711 | 0.090 |
Why?
|
| Faculty | 1 | 2013 | 95 | 0.090 |
Why?
|
| Staphylococcal Infections | 1 | 2017 | 569 | 0.090 |
Why?
|
| Demography | 2 | 2024 | 243 | 0.090 |
Why?
|
| Computer-Assisted Instruction | 1 | 2012 | 58 | 0.090 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 1 | 2011 | 8 | 0.090 |
Why?
|
| Signal Transduction | 1 | 2024 | 4683 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2018 | 1099 | 0.090 |
Why?
|
| Health Resources | 1 | 2012 | 128 | 0.090 |
Why?
|
| Immunoglobulin M | 1 | 2011 | 213 | 0.080 |
Why?
|
| Staining and Labeling | 2 | 2022 | 172 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2017 | 707 | 0.080 |
Why?
|
| Erythrocytes | 1 | 2011 | 191 | 0.080 |
Why?
|
| Iatrogenic Disease | 1 | 2011 | 121 | 0.080 |
Why?
|
| Neuropsychological Tests | 2 | 2004 | 997 | 0.080 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 149 | 0.080 |
Why?
|
| Neurilemmoma | 1 | 2009 | 42 | 0.070 |
Why?
|
| Clinical Protocols | 1 | 2010 | 228 | 0.070 |
Why?
|
| Glioma | 1 | 2014 | 498 | 0.070 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2009 | 63 | 0.070 |
Why?
|
| Academies and Institutes | 1 | 2009 | 81 | 0.070 |
Why?
|
| Injections | 1 | 2009 | 114 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 741 | 0.070 |
Why?
|
| Safety Management | 1 | 2009 | 111 | 0.070 |
Why?
|
| Intraoperative Complications | 1 | 2009 | 156 | 0.070 |
Why?
|
| Medical Errors | 1 | 2009 | 152 | 0.070 |
Why?
|
| Mentors | 1 | 2009 | 160 | 0.070 |
Why?
|
| Retreatment | 1 | 2007 | 87 | 0.060 |
Why?
|
| Arachnoiditis | 1 | 2006 | 1 | 0.060 |
Why?
|
| Circle of Willis | 1 | 2006 | 2 | 0.060 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2006 | 7 | 0.060 |
Why?
|
| Spinal Stenosis | 1 | 2006 | 9 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 1626 | 0.060 |
Why?
|
| International Cooperation | 1 | 2007 | 161 | 0.060 |
Why?
|
| Dansyl Compounds | 1 | 1986 | 4 | 0.060 |
Why?
|
| Employment | 1 | 2006 | 71 | 0.060 |
Why?
|
| Membranes | 1 | 1986 | 16 | 0.060 |
Why?
|
| Retinal Neovascularization | 1 | 2006 | 12 | 0.060 |
Why?
|
| Biometry | 2 | 2023 | 102 | 0.060 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2005 | 6 | 0.060 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2005 | 34 | 0.060 |
Why?
|
| Laser Therapy | 1 | 2008 | 239 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 393 | 0.060 |
Why?
|
| Orbit Evisceration | 1 | 2025 | 6 | 0.060 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2005 | 70 | 0.060 |
Why?
|
| Lumbar Vertebrae | 1 | 2006 | 109 | 0.060 |
Why?
|
| Occult Blood | 1 | 2005 | 33 | 0.060 |
Why?
|
| Nerve Compression Syndromes | 1 | 2005 | 15 | 0.060 |
Why?
|
| Bioprinting | 1 | 2025 | 13 | 0.060 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2005 | 59 | 0.060 |
Why?
|
| Infarction | 1 | 2025 | 20 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 1256 | 0.060 |
Why?
|
| Debridement | 1 | 2025 | 90 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2012 | 1489 | 0.060 |
Why?
|
| United States Food and Drug Administration | 1 | 2005 | 156 | 0.060 |
Why?
|
| Calcium Channel Blockers | 1 | 2024 | 111 | 0.050 |
Why?
|
| Axons | 1 | 2007 | 385 | 0.050 |
Why?
|
| Self Disclosure | 1 | 2004 | 28 | 0.050 |
Why?
|
| Weight Gain | 1 | 2007 | 384 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 743 | 0.050 |
Why?
|
| Camelids, New World | 1 | 2024 | 4 | 0.050 |
Why?
|
| Vitamin B 12 | 1 | 2024 | 59 | 0.050 |
Why?
|
| Gastric Bypass | 1 | 2005 | 96 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2025 | 283 | 0.050 |
Why?
|
| Tomography, Emission-Computed | 1 | 2004 | 36 | 0.050 |
Why?
|
| Eyeglasses | 1 | 2023 | 10 | 0.050 |
Why?
|
| Vision Tests | 1 | 2004 | 27 | 0.050 |
Why?
|
| Leucovorin | 1 | 2004 | 54 | 0.050 |
Why?
|
| Colitis | 1 | 2005 | 159 | 0.050 |
Why?
|
| Parietal Lobe | 1 | 2004 | 47 | 0.050 |
Why?
|
| Cross Reactions | 1 | 2004 | 187 | 0.050 |
Why?
|
| Skull Base | 1 | 2004 | 48 | 0.050 |
Why?
|
| Mice | 1 | 2021 | 18487 | 0.050 |
Why?
|
| Radiotherapy, Conformal | 1 | 2003 | 51 | 0.050 |
Why?
|
| Blood Cell Count | 1 | 2023 | 64 | 0.050 |
Why?
|
| Conjunctival Diseases | 1 | 2003 | 28 | 0.050 |
Why?
|
| Protein Binding | 3 | 1994 | 1712 | 0.050 |
Why?
|
| Electrolytes | 1 | 2023 | 58 | 0.050 |
Why?
|
| Vincristine | 1 | 2004 | 194 | 0.050 |
Why?
|
| Tonometry, Ocular | 1 | 2023 | 29 | 0.050 |
Why?
|
| Knowledge Bases | 1 | 2023 | 40 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2004 | 126 | 0.050 |
Why?
|
| Endocarditis, Bacterial | 1 | 2004 | 133 | 0.050 |
Why?
|
| RNA, Bacterial | 1 | 2002 | 58 | 0.050 |
Why?
|
| Journal Impact Factor | 1 | 2022 | 25 | 0.050 |
Why?
|
| Obesity, Morbid | 1 | 2005 | 233 | 0.050 |
Why?
|
| Workload | 1 | 2003 | 154 | 0.050 |
Why?
|
| Bibliometrics | 1 | 2022 | 39 | 0.050 |
Why?
|
| Crohn Disease | 1 | 2005 | 291 | 0.050 |
Why?
|
| Anecdotes as Topic | 1 | 2002 | 3 | 0.050 |
Why?
|
| Photography | 1 | 2023 | 80 | 0.050 |
Why?
|
| Altitude | 1 | 2022 | 23 | 0.050 |
Why?
|
| Traction | 1 | 2021 | 10 | 0.050 |
Why?
|
| Health Services Research | 1 | 2003 | 178 | 0.040 |
Why?
|
| Positive-Pressure Respiration | 1 | 2002 | 83 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2004 | 442 | 0.040 |
Why?
|
| Cerebral Arteries | 1 | 2002 | 80 | 0.040 |
Why?
|
| HIV Infections | 1 | 2013 | 2037 | 0.040 |
Why?
|
| Ambulatory Care Facilities | 1 | 2003 | 236 | 0.040 |
Why?
|
| Virulence | 1 | 2021 | 271 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2002 | 492 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2007 | 1695 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2002 | 803 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2003 | 409 | 0.040 |
Why?
|
| Cerebrospinal Fluid Leak | 1 | 2020 | 50 | 0.040 |
Why?
|
| Circadian Rhythm | 1 | 2022 | 316 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2003 | 834 | 0.040 |
Why?
|
| Prescription Drugs | 1 | 2020 | 52 | 0.040 |
Why?
|
| Posture | 1 | 2020 | 136 | 0.040 |
Why?
|
| Axilla | 1 | 2019 | 43 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2019 | 132 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2023 | 506 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2002 | 453 | 0.040 |
Why?
|
| Sepsis | 1 | 2003 | 501 | 0.040 |
Why?
|
| Rupture, Spontaneous | 1 | 2018 | 48 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2005 | 1306 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2018 | 80 | 0.030 |
Why?
|
| Aorta, Thoracic | 1 | 2002 | 536 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2025 | 3101 | 0.030 |
Why?
|
| Mass Screening | 1 | 2003 | 825 | 0.030 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 1617 | 0.030 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2004 | 742 | 0.030 |
Why?
|
| Pulse Therapy, Drug | 1 | 2015 | 10 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 647 | 0.030 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2015 | 40 | 0.030 |
Why?
|
| Obesity | 1 | 2007 | 2390 | 0.030 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2015 | 18 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 677 | 0.030 |
Why?
|
| Amines | 1 | 2015 | 37 | 0.030 |
Why?
|
| Olivary Nucleus | 1 | 2015 | 14 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 1235 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2017 | 769 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2015 | 197 | 0.030 |
Why?
|
| Vertigo | 1 | 2014 | 35 | 0.030 |
Why?
|
| Ca(2+) Mg(2+)-ATPase | 1 | 1994 | 4 | 0.030 |
Why?
|
| Bromine | 1 | 1994 | 3 | 0.030 |
Why?
|
| Sensory Thresholds | 1 | 2014 | 32 | 0.030 |
Why?
|
| Lipid Bilayers | 1 | 1994 | 46 | 0.030 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2015 | 179 | 0.030 |
Why?
|
| Neurosurgical Procedures | 1 | 2016 | 316 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2017 | 485 | 0.020 |
Why?
|
| Intracranial Thrombosis | 1 | 2013 | 12 | 0.020 |
Why?
|
| Cranial Sinuses | 1 | 2013 | 14 | 0.020 |
Why?
|
| Encephalitis, Varicella Zoster | 1 | 2012 | 1 | 0.020 |
Why?
|
| Uveitis, Anterior | 1 | 2012 | 5 | 0.020 |
Why?
|
| Acyclovir | 1 | 2012 | 47 | 0.020 |
Why?
|
| Herpesvirus 3, Human | 1 | 2012 | 30 | 0.020 |
Why?
|
| Periaqueductal Gray | 1 | 2011 | 5 | 0.020 |
Why?
|
| Anticonvulsants | 1 | 2015 | 391 | 0.020 |
Why?
|
| 14-3-3 Proteins | 1 | 2011 | 57 | 0.020 |
Why?
|
| Basal Ganglia | 1 | 2011 | 61 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2012 | 451 | 0.020 |
Why?
|
| Down Syndrome | 1 | 2013 | 233 | 0.020 |
Why?
|
| tau Proteins | 1 | 2011 | 258 | 0.020 |
Why?
|
| Purpura | 1 | 2008 | 26 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2009 | 135 | 0.020 |
Why?
|
| Physician Executives | 1 | 2008 | 34 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2008 | 282 | 0.020 |
Why?
|
| Schools, Medical | 1 | 2008 | 115 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2011 | 869 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 1831 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2006 | 142 | 0.020 |
Why?
|
| Data Collection | 1 | 2008 | 371 | 0.020 |
Why?
|
| Sigmoidoscopy | 1 | 2005 | 11 | 0.010 |
Why?
|
| Oral Ulcer | 1 | 2005 | 5 | 0.010 |
Why?
|
| Photochemotherapy | 1 | 2006 | 40 | 0.010 |
Why?
|
| Linear Models | 1 | 2007 | 695 | 0.010 |
Why?
|
| Ulcer | 1 | 2005 | 51 | 0.010 |
Why?
|
| Genital Diseases, Female | 1 | 2005 | 32 | 0.010 |
Why?
|
| Health Status | 1 | 2007 | 387 | 0.010 |
Why?
|
| Metronidazole | 1 | 2005 | 161 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2008 | 595 | 0.010 |
Why?
|
| Periodontal Abscess | 1 | 2003 | 2 | 0.010 |
Why?
|
| Lung Abscess | 1 | 2003 | 15 | 0.010 |
Why?
|
| Malingering | 1 | 2004 | 25 | 0.010 |
Why?
|
| Diarrhea | 1 | 2005 | 311 | 0.010 |
Why?
|
| Binding Sites | 1 | 1986 | 1202 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 2002 | 65 | 0.010 |
Why?
|
| Age Factors | 1 | 2008 | 2872 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2005 | 566 | 0.010 |
Why?
|
| Radiography | 1 | 2003 | 762 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 2143 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2003 | 265 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 2297 | 0.010 |
Why?
|